Fcγ receptors and ligands and cardiovascular disease

Circulation Research

Volumn 116, Issue 2, 2015, Pages 368-384

  Tanigaki, Keiji ^a   Sundgren, Nathan ^a   Khera, Amit ^a   Vongpatanasin, Wanpen ^a   Mineo, Chieko ^a   Shaul, Philip W ^a  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

atherosclerosis; C reactive protein; hypertension; nitric oxide synthase type III

Indexed keywords

C REACTIVE PROTEIN; FC RECEPTOR; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; LIGAND; PENTRAXIN; RECEPTOR SUBTYPE;

ANTIGEN ANTIBODY COMPLEX; ATHEROSCLEROSIS; BLOOD VESSEL INJURY; BLOOD VESSEL OCCLUSION; CARDIOVASCULAR DISEASE; ENDOTHELIUM CELL; HEART INFARCTION; HUMAN; HYPERTENSION; INSULIN RESISTANCE; LEUKOCYTE; NONHUMAN; PRIORITY JOURNAL; REVIEW; THROMBOCYTE; THROMBOSIS; VASCULAR SMOOTH MUSCLE; ANIMAL; CELLULAR IMMUNITY; IMMUNOLOGY; METABOLISM; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; HUMANS; IMMUNITY, CELLULAR; LIGANDS; RECEPTORS, IGG; SIGNAL TRANSDUCTION;

EID: 84921984859     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.116.302795     Document Type: Review

References (174)

1. Ravetch JV, Bolland S. IgG Fc receptors. Annu Rev Immunol. 2001;19:275-290. doi:10.1146/annurev.immunol.19.1.275.
2. Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol. 2008;8:34-47. doi:10.1038/nri2206.
3. Nimmerjahn F, Ravetch JV. Fcgamma receptors: old friends and new family members. Immunity. 2006;24:19-28. doi:10.1016/j.immuni.2005.11.010.
4. Ravetch JV, Kinet JP. Fc receptors. Annu Rev Immunol. 1991;9:457-492. doi:10.1146/annurev.iy.09.040191.002325.
5. van de Winkel JG, Anderson CL. Biology of human immunoglobulin G Fc receptors. J Leukoc Biol 1991;49:511-524.
6. Rothe G, Gabriel H, Kovacs E, Klucken J, Stöhr J, Kindermann W, Schmitz G. Peripheral blood mononuclear phagocyte subpopulations as cellular markers in hypercholesterolemia. Arterioscler Thromb Vasc Biol. 1996;16:1437-1447.
7. Dhodapkar KM, Banerjee D, Connolly J, Kukreja A, Matayeva E, Veri MC, Ravetch JV, Steinman RM, Dhodapkar MV. Selective blockade of the inhibitory Fcgamma receptor (FcgammaRIIB) in human dendritic cells and monocytes induces a type I interferon response program. J Exp Med. 2007;204:1359-1360. doi:10.1084/jem.20062545.
8. Molfetta R, Quatrini L, Gasparrini F, Zitti B, Santoni A, Paolini R. Regulation of fc receptor endocytic trafficking by ubiquitination. Front Immunol. 2014;5:449. doi:10.3389/fimmu.2014.00449.
9. Devaraj S, Du Clos TW, Jialal I. Binding and internalization of C-reactive protein by Fcgamma receptors on human aortic endothelial cells mediates biological effects. Arterioscler Thromb Vasc Biol. 2005;25:1359-1363. doi:10.1161/01.ATV.0000168573.10844.ae.
10. Bruhns P. Properties of mouse and human IgG receptors and their contribution to disease models. Blood. 2012;119:5640-5649. doi:10.1182/blood-2012-01-380121.
11. Du Clos TW. Function of C-reactive protein. Ann Med. 2000;32:274-278.
12. Du Clos TW. Pentraxins: structure, function, and role in inflammation. ISRN Inflamm. 2013;2013:379040. doi:10.1155/2013/379040.
13. Du Clos TW, Mold C. The role of C-reactive protein in the resolution of bacterial infection. Curr Opin Infect Dis. 2001;14:289-293.
14. Yeh ET, Anderson HV, Pasceri V, Willerson JT. C-reactive protein: linking inflammation to cardiovascular complications. Circulation. 2001;104:974-975.
15. Yasojima K, Schwab C, McGeer EG, McGeer PL. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol. 2001;158:1039-1051. doi:10.1016/S0002-9440(10)64051-5.
16. Kuji T, Masaki T, Li L, Cheung AK. Expression of C-reactive protein in myointimal hyperplasia in a porcine arteriovenous graft model. Nephrol Dial Transplant. 2007;22:2469-2475. doi:10.1093/ndt/gfm240.
17. Venugopal SK, Devaraj S, Jialal I. Macrophage conditioned medium induces the expression of C-reactive protein in human aortic endothelial cells: potential for paracrine/autocrine effects. Am J Pathol. 2005;166:1265-1271. doi:10.1016/S0002-9440(10)62345-0.
18. Chu CS, Wang YC, Lu LS, Walton B, Yilmaz HR, Huang RY, Sawamura T, Dixon RA, Lai WT, Chen CH, Lu J. Electronegative low-density lipoprotein increases C-reactive protein expression in vascular endothelial cells through the LOX-1 receptor. PLoS One. 2013;8:e70533. doi:10.1371/journal. pone.0070533.
19. Pang X, Liu J, Zhao J, Mao J, Zhang X, Feng L, Han C, Li M, Wang S, Wu D. Homocysteine induces the expression of C-reactive protein via NMDAr-ROS-MAPK-NF-?B signal pathway in rat vascular smooth muscle cells. Atherosclerosis. 2014;236:73-81. doi:10.1016/j. atherosclerosis.2014.06.021.
20. Peng N, Liu JT, Gao DF, Lin R, Li R. Angiotensin II-induced C-reactive protein generation: inflammatory role of vascular smooth muscle cells in atherosclerosis. Atherosclerosis. 2007;193:292-298. doi:10.1016/j. atherosclerosis.2006.09.007.
21. Wang C, Liu J, Guo F, Ji Y, Liu N. Endothelin-1 induces the expression of C-reactive protein in rat vascular smooth muscle cells. Biochem Biophys Res Commun. 2009;389:537-542. doi:10.1016/j.bbrc.2009.09.023.
22. Memoli B, Procino A, Calabrò P, Esposito P, Grandaliano G, Pertosa G, Prete MD, Andreucci M, Lillo SD, Ferulano G, Cillo C, Savastano S, Colao A, Guida B. Inflammation may modulate IL-6 and C-reactive protein gene expression in the adipose tissue: the role of IL-6 cell membrane receptor. Am J Physiol Endocrinol Metab. 2007;293:E1030-E1035. doi:10.1152/ajpendo.00697.2006.
23. Ouchi N, Kihara S, Funahashi T, Nakamura T, Nishida M, Kumada M, Okamoto Y, Ohashi K, Nagaretani H, Kishida K, Nishizawa H, Maeda N, Kobayashi H, Hiraoka H, Matsuzawa Y. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation. 2003;107:671-674.
24. Anty R, Bekri S, Luciani N, Saint-Paul MC, Dahman M, Iannelli A, Amor IB, Staccini-Myx A, Huet PM, Gugenheim J, Sadoul JL, Le Marchand-Brustel Y, Tran A, Gual P. The inflammatory C-reactive protein is increased in both liver and adipose tissue in severely obese patients independently from metabolic syndrome, Type 2 diabetes, and NASH. Am J Gastroenterol. 2006;101:1824-1833. doi:10.1111/j.1572-0241.2006.00724.x.
25. Diehl EE, Haines GK 3rd, Radosevich JA, Potempa LA. Immunohistochemical localization of modified C-reactive protein antigen in normal vascular tissue. Am J Med. Sci. 2000;319:79-83.
26. Potempa LA, Maldonado BA, Laurent P, Zemel ES, Gewurz H. Antigenic, electrophoretic and binding alterations of human C-reactive protein modified selectively in the absence of calcium. Mol Immunol. 1983;20:1165-1175.
27. Rees RF, Gewurz H, Siegel JN, Coon J, Potempa LA. Expression of a C-reactive protein neoantigen (neo-CRP) in inflamed rabbit liver and muscle. Clin Immunol Immunopathol. 1988;48:95-107.
28. Eisenhardt SU, Habersberger J, Murphy A, Chen YC, Woollard KJ, Bassler N, Qian H, von Zur Muhlen C, Hagemeyer CE, Ahrens I, Chin-Dusting J, Bobik A, Peter K. Dissociation of pentameric to monomeric C-reactive protein on activated platelets localizes inflammation to atherosclerotic plaques. Circ Res. 2009;105:128-137. doi:10.1161/CIRCRESAHA.108.190611.
29. Khreiss T, József L, Potempa LA, Filep JG. Conformational rearrangement in C-reactive protein is required for proinflammatory actions on human endothelial cells. Circulation. 2004;109:2016-2022. doi:10.1161/01. CIR.0000125527.41598.68.
30. Sundgren NC, Zhu W, Yuhanna IS, Chambliss KL, Ahmed M, Tanigaki K, Umetani M, Mineo C, Shaul PW. Coupling of Fc? receptor I to Fc? receptor IIb by SRC kinase mediates C-reactive protein impairment of endothelial function. Circ Res. 2011;109:1132-1140. doi:10.1161/CIRCRESAHA.111.254573.
31. Ji SR, Ma L, Bai CJ, Shi JM, Li HY, Potempa LA, Filep JG, Zhao J, Wu Y. Monomeric C-reactive protein activates endothelial cells via interaction with lipid raft microdomains. FASEB J. 2009;23:1806-1816. doi:10.1096/fj.08-116962.
32. Schwedler SB, Kuhlencordt PJ, Ponnuswamy PP, Hatiboglu G, Quaschning T, Widder J, Wanner C, Potempa LA, Galle J. Native C-reactive protein induces endothelial dysfunction in ApoE-/-mice: implications for iNOS and reactive oxygen species. Atherosclerosis. 2007;195:e76-e84. doi:10.1016/j.atherosclerosis.2007.06.013.
33. Crowell RE, Du Clos TW, Montoya G, Heaphy E, Mold C. C-reactive protein receptors on the human monocytic cell line U-937. Evidence for additional binding to Fc gamma RI. J Immunol. 1991;147:3445-3451.
34. Marnell LL, Mold C, Volzer MA, Burlingame RW, Du Clos TW. C-reactive protein binds to Fc gamma RI in transfected COS cells. J Immunol. 1995;155:2185-2193.
35. Bharadwaj D, Stein MP, Volzer M, Mold C, Du Clos TW. The major receptor for C-reactive protein on leukocytes is fcgamma receptor II. J Exp Med. 1999;190:585-590.
36. Stein MP, Edberg JC, Kimberly RP, Mangan EK, Bharadwaj D, Mold C, Du Clos TW. C-reactive protein binding to FcgammaRIIa on human monocytes and neutrophils is allele-specific. J Clin Invest. 2000;105:369-376. doi:10.1172/JCI7817.
37. Stein MP, Mold C, Du Clos TW. C-reactive protein binding to murine leukocytes requires Fc gamma receptors. J Immunol. 2000;164:1514-1520.
38. Mold C, Baca R, Du Clos TW. Serum amyloid P component and C-reactive protein opsonize apoptotic cells for phagocytosis through Fcgamma receptors. J Autoimmun. 2002;19:147-154.
39. Lu J, Marnell LL, Marjon KD, Mold C, Du Clos TW, Sun PD. Structural recognition and functional activation of FcgammaR by innate pentraxins. Nature. 2008;456:989-992. doi:10.1038/nature07468.
40. Venugopal SK, Devaraj S, Yuhanna I, Shaul P, Jialal I. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation. 2002;106:1439-1441.
41. Devaraj S, Xu DY, Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation. 2003;107:398-404.
42. Devaraj S, Kumaresan PR, Jialal I. Effect of C-reactive protein on chemokine expression in human aortic endothelial cells. J Mol Cell Cardiol. 2004;36:405-410. doi:10.1016/j.yjmcc.2003.12.005.
43. Devaraj S, Davis B, Simon SI, Jialal I. CRP promotes monocyte-endothelial cell adhesion via Fcgamma receptors in human aortic endothelial cells under static and shear flow conditions. Am J Physiol Heart Circ Physiol. 2006;291:H1170-H1176. doi:10.1152/ajpheart.00150.2006.
44. Schwartz R, Osborne-Lawrence S, Hahner L, Gibson LL, Gormley AK, Vongpatanasin W, Zhu W, Word RA, Seetharam D, Black S, Samols D, Mineo C, Shaul PW. C-reactive protein downregulates endothelial NO synthase and attenuates reendothelialization in vivo in mice. Circ Res. 2007;100:1452-1459. doi:10.1161/01.RES.0000267745.03488.47.
45. Mineo C, Gormley AK, Yuhanna IS, Osborne-Lawrence S, Gibson LL, Hahner L, Shohet RV, Black S, Salmon JE, Samols D, Karp DR, Thomas GD, Shaul PW. FcgammaRIIB mediates C-reactive protein inhibition of endothelial NO synthase. Circ Res. 2005;97:1124-1131. doi:10.1161/01. RES.0000194323.77203.fe.
46. Hein TW, Singh U, Vasquez-Vivar J, Devaraj S, Kuo L, Jialal I. Human C-reactive protein induces endothelial dysfunction and uncoupling of eNOS in vivo. Atherosclerosis. 2009;206:61-68. doi:10.1016/j. atherosclerosis.2009.02.002.
47. Black S, Kushner I, Samols D. C-reactive Protein. J Biol Chem. 2004;279:48487-48490. doi:10.1074/jbc.R400025200.
48. Teoh H, Quan A, Lovren F, Wang G, Tirgari S, Szmitko PE, Szalai AJ, Ward ME, Verma S. Impaired endothelial function in C-reactive protein overexpressing mice. Atherosclerosis. 2008;201:318-325. doi:10.1016/j. atherosclerosis.2008.02.034.
49. Tanigaki K, Mineo C, Yuhanna IS, Chambliss KL, Quon MJ, Bonvini E, Shaul PW. C-reactive protein inhibits insulin activation of endothelial nitric oxide synthase via the immunoreceptor tyrosine-based inhibition motif of FcgammaRIIB and SHIP-1. Circ Res. 2009;104:1275-1282. doi:10.1161/CIRCRESAHA.108.192906.
50. Muniyappa R, Montagnani M, Koh KK, Quon MJ. Cardiovascular actions of insulin. Endocr Rev. 2007;28:463-491. doi:10.1210/er.2007-0006.
51. Veri MC, Gorlatov S, Li H, Burke S, Johnson S, Stavenhagen J, Stein KE, Bonvini E, Koenig S. Monoclonal antibodies capable of discriminating the human inhibitory Fcgamma-receptor IIB (CD32B) from the activating Fcgamma-receptor IIA (CD32A): biochemical, biological and functional characterization. Immunology. 2007;121:392-404. doi:10.1111/j.1365-2567.2007.02588.x.
52. Blaschke F, Bruemmer D, Yin F, Takata Y, Wang W, Fishbein MC, Okura T, Higaki J, Graf K, Fleck E, Hsueh WA, Law RE. C-reactive protein induces apoptosis in human coronary vascular smooth muscle cells. Circulation. 2004;110:579-587. doi:10.1161/01.CIR.0000136999. 77584.A2.
53. Ryu J, Lee CW, Shin JA, Park CS, Kim JJ, Park SJ, Han KH. FcgammaRIIa mediates C-reactive protein-induced inflammatory responses of human vascular smooth muscle cells by activating NADPH oxidase 4. Cardiovasc Res. 2007;75:555-565. doi:10.1016/j.cardiores.2007.04.027.
54. Hattori Y, Matsumura M, Kasai K. Vascular smooth muscle cell activation by C-reactive protein. Cardiovasc Res. 2003;58:186-195.
55. Doronzo G, Russo I, Mattiello L, Trovati M, Anfossi G. C-reactive protein increases matrix metalloproteinase-2 expression and activity in cultured human vascular smooth muscle cells. J Lab Clin Med. 2005;146:287-298. doi:10.1016/j.lab.2005.07.010.
56. Wu J, Stevenson MJ, Brown JM, Grunz EA, Strawn TL, Fay WP. C-reactive protein enhances tissue factor expression by vascular smooth muscle cells: mechanisms and in vivo significance. Arterioscler Thromb Vasc Biol. 2008;28:698-704. doi:10.1161/ATVBAHA.107.160903.
57. Wang CH, Li SH, Weisel RD, Fedak PW, Dumont AS, Szmitko P, Li RK, Mickle DA, Verma S. C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation. 2003;107:1783-1790. doi:10.1161/01.CIR.0000061916.95736.E5.
58. Lopes-Virella MF, Binzafar N, Rackley S, Takei A, La Via M, Virella G. The uptake of LDL-IC by human macrophages: predominant involvement of the Fc gamma RI receptor. Atherosclerosis. 1997;135:161-170.
59. Huang Y, Fleming AJ, Wu S, Virella G, Lopes-Virella MF. Fc-gamma receptor cross-linking by immune complexes induces matrix metalloproteinase-1 in U937 cells via mitogen-activated protein kinase. Arterioscler Thromb Vasc Biol. 2000;20:2533-2538.
60. Luo Y, Pollard JW, Casadevall A. Fcgamma receptor cross-linking stimulates cell proliferation of macrophages via the ERK pathway. J Biol Chem. 2010;285:4232-4242. doi:10.1074/jbc.M109.037168.
61. Oksjoki R, Kovanen PT, Lindstedt KA, Jansson B, Pentikaïnen MO. OxLDL-IgG immune complexes induce survival of human monocytes. Arterioscler Thromb Vasc Biol. 2006;26:576-583. doi:10.1161/01. ATV.0000201041.14438.8d.
62. Hansson GK, Bondjers G, Bylock A, Hjalmarsson L. Ultrastructural studies on the localization of IgG in the aortic endothelium and subendothelial intima of atherosclerotic and nonatherosclerotic rabbits. Exp Mol Pathol. 1980;33:302-315.
63. Parums D, Mitchinson MJ. Demonstration of immunoglobulin in the neighbourhood of advanced atherosclerotic plaques. Atherosclerosis. 1981;38:211-216.
64. Ylä-Herttuala S, Palinski W, Butler SW, Picard S, Steinberg D, Witztum JL. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler Thromb. 1994;14:32-40.
65. Boulaftali Y, Hess PR, Kahn ML, Bergmeier W. Platelet immunoreceptor tyrosine-based activation motif (ITAM) signaling and vascular integrity. Circ Res. 2014;114:1174-1184. doi:10.1161/CIRCRESAHA. 114.301611.
66. Cines DB, Schreiber AD. Immune thrombocytopenia. Use of a Coombs antiglobulin test to detect IgG and C3 on platelets. N Engl J Med. 1979;300:106-111. doi:10.1056/NEJM197901183000302.
67. Clawson CC, Rao GH, White JG. Platelet interaction with bacteria. IV. Stimulation of the release reaction. Am J Pathol. 1975;81:411-420.
68. Davoren A, Aster RH. Heparin-induced thrombocytopenia and thrombosis. Am J Hematol. 2006;81:36-44. doi:10.1002/ajh.20490.
69. Reilly MP, McKenzie SE. Insights from mouse models of heparin-induced thrombocytopenia and thrombosis. Curr Opin Hematol. 2002;9:395-400.
70. Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol. 2003;121:535-555.
71. Cox D, Kerrigan SW, Watson SP. Platelets and the innate immune system: mechanisms of bacterial-induced platelet activation. J Thromb Haemost. 2011;9:1097-1107. doi:10.1111/j.1538-7836.2011.04264.x.
72. Fitzgerald JR, Foster TJ, Cox D. The interaction of bacterial pathogens with platelets. Nat Rev Microbiol. 2006;4:445-457. doi:10.1038/nrmicro1425.
73. McKenzie SE, Taylor SM, Malladi P, Yuhan H, Cassel DL, Chien P, Schwartz E, Schreiber AD, Surrey S, Reilly MP. The role of the human Fc receptor Fc gamma RIIA in the immune clearance of platelets: a transgenic mouse model. J Immunol. 1999;162:4311-4318.
74. Hansson GK, Libby P, Schönbeck U, Yan ZQ. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res. 2002;91:281-291.
75. Hernández-Vargas P, Ortiz-Munõz G, López-Franco O, Suzuki Y, Gallego-Delgado J, Sanjuán G, Lázaro A, López-Parra V, Ortega L, Egido J, Gómez-Guerrero C. Fcgamma receptor deficiency confers protection against atherosclerosis in apolipoprotein E knockout mice. Circ Res. 2006;99:1188-1196. doi:10.1161/01.RES.0000250556.07796.6c.
76. Sumiyoshi K, Mokuno H, Iesaki T, Shimada K, Miyazaki T, Kume A, Kiyanagi T, Kuremoto K, Watanabe Y, Tada N, Daida H. Deletion of the Fc receptors gamma chain preserves endothelial function affected by hypercholesterolaemia in mice fed on a high-fat diet. Cardiovasc Res. 2008;80:463-470. doi:10.1093/cvr/cvn206.
77. Mallavia B, Oguiza A, Lopez-Franco O, Recio C, Ortiz-Munõz G, Lazaro I, Lopez-Parra V, Egido J, Gomez-Guerrero C. Gene deficiency in activating Fc? receptors influences the macrophage phenotypic balance and reduces atherosclerosis in mice. PLoS One. 2013;8:e66754. doi:10.1371/journal.pone.0066754.
78. Ng HP, Burris RL, Nagarajan S. Attenuated atherosclerotic lesions in apoE-Fc?-chain-deficient hyperlipidemic mouse model is associated with inhibition of Th17 cells and promotion of regulatory T cells. J Immunol. 2011;187:6082-6093. doi:10.4049/jimmunol.1004133.
79. Kelly JA, Griffin ME, Fava RA, Wood SG, Bessette KA, Miller ER, Huber SA, Binder CJ, Witztum JL, Morganelli PM. Inhibition of arterial lesion progression in CD16-deficient mice: evidence for altered immunity and the role of IL-10. Cardiovasc Res. 2010;85:224-231. doi:10.1093/cvr/cvp300.
80. Mendez-Fernandez YV, Stevenson BG, Diehl CJ, Braun NA, Wade NS, Covarrubias R, van Leuven S, Witztum JL, Major AS. The inhibitory Fc?RIIb modulates the inflammatory response and influences atherosclerosis in male apoE(-/-) mice. Atherosclerosis. 2011;214:73-80. doi:10.1016/j.atherosclerosis.2010.10.018.
81. Zhao M, Wigren M, Dunér P, Kolbus D, Olofsson KE, Björkbacka H, Nilsson J, Fredrikson GN. FcgammaRIIB inhibits the development of atherosclerosis in low-density lipoprotein receptor-deficient mice. J Immunol. 2010;184:2253-2260. doi:10.4049/jimmunol.0902654.
82. Nicoletti A, Kaveri S, Caligiuri G, Bariéty J, Hansson GK. Immunoglobulin treatment reduces atherosclerosis in apo E knockout mice. J Clin Invest. 1998;102:910-918. doi:10.1172/JCI119892.
83. Paul A, Ko KW, Li L, Yechoor V, McCrory MA, Szalai AJ, Chan L. C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2004;109:647-655. doi:10.1161/01. CIR.0000114526.50618.24.
84. Hirschfield GM, Gallimore JR, Kahan MC, Hutchinson WL, Sabin CA, Benson GM, Dhillon AP, Tennent GA, Pepys MB. Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice. Proc Natl Acad Sci USA. 2005;102:8309-8314. doi:10.1073/pnas.0503202102.
85. Tennent GA, Hutchinson WL, Kahan MC, Hirschfield GM, Gallimore JR, Lewin J, Sabin CA, Dhillon AP, Pepys MB. Transgenic human CRP is not pro-atherogenic, pro-atherothrombotic or pro-inflammatory in apoE-/-mice. Atherosclerosis. 2008;196:248-255. doi:10.1016/j. atherosclerosis.2007.05.010.
86. Trion A, de Maat MP, Jukema JW, van der Laarse A, Maas MC, Offerman EH, Havekes LM, Szalai AJ, Princen HM, Emeis JJ. No effect of C-reactive protein on early atherosclerosis development in apolipoprotein E∗3-leiden/human C-reactive protein transgenic mice. Arterioscler Thromb Vasc Biol. 2005;25:1635-1640. doi:10.1161/01. ATV.0000171992.36710.1e.
87. Kovacs A, Tornvall P, Nilsson R, Tegnér J, Hamsten A, Björkegren J. Human C-reactive protein slows atherosclerosis development in a mouse model with human-like hypercholesterolemia. Proc Natl Acad Sci USA. 2007;104:13768-13773. doi:10.1073/pnas.0706027104.
88. Ortiz MA, Campana GL, Woods JR, Boguslawski G, Sosa MJ, Walker CL, Labarrere CA. Continuously-infused human C-reactive protein is neither proatherosclerotic nor proinflammatory in apolipoprotein E-deficient mice. Exp Biol Med (Maywood). 2009;234:624-631. doi:10.3181/0812-RM-347.
89. Koike T, Kitajima S, Yu Y, Nishijima K, Zhang J, Ozaki Y, Morimoto M, Watanabe T, Bhakdi S, Asada Y, Chen YE, Fan J. Human C-reactive protein does not promote atherosclerosis in transgenic rabbits. Circulation. 2009;120:2088-2094. doi:10.1161/CIRCULATIONAHA.109.872796.
90. Teupser D, Weber O, Rao TN, Sass K, Thiery J, Fehling HJ. No reduction of atherosclerosis in C-reactive protein (CRP)-deficient mice. J Biol Chem. 2011;286:6272-6279. doi:10.1074/jbc.M110.161414.
91. Yu Q, Liu Z, Waqar AB, Ning B, Yang X, Shiomi M, Graham MJ, Crooke RM, Liu E, Dong S, Fan J. Effects of antisense oligonucleotides against C-reactive protein on the development of atherosclerosis in WHHL rabbits. Mediators Inflamm. 2014;2014:979132. doi:10.1155/2014/979132.
92. Wang D, Oparil S, Chen YF, McCrory MA, Skibinski GA, Feng W, Szalai AJ. Estrogen treatment abrogates neointima formation in human C-reactive protein transgenic mice. Arterioscler Thromb Vasc Biol. 2005;25:2094-2099. doi:10.1161/01.ATV.0000179602.85797.3f.
93. Xing D, Hage FG, Chen YF, McCrory MA, Feng W, Skibinski GA, Majid-Hassan E, Oparil S, Szalai AJ. Exaggerated neointima formation in human C-reactive protein transgenic mice is IgG Fc receptor type I (Fc gamma RI)-dependent. Am J Pathol. 2008;172:22-30. doi:10.2353/ajpath.2008.070154.
94. Danenberg HD, Szalai AJ, Swaminathan RV, Peng L, Chen Z, Seifert P, Fay WP, Simon DI, Edelman ER. Increased thrombosis after arterial injury in human C-reactive protein-transgenic mice. Circulation. 2003;108:512-515. doi:10.1161/01.CIR.0000085568.13915.1E.
95. Danenberg HD, Grad E, Swaminathan RV, Chen Z, Seifert P, Szalai AJ, Lotan C, Simon DI, Edelman ER. Neointimal formation is reduced after arterial injury in human crp transgenic mice. Atherosclerosis. 2008;201:85-91. doi:10.1016/j.atherosclerosis.2008.01.013.
96. Konishi H, Katoh Y, Takaya N, Kashiwakura Y, Itoh S, Ra C, Daida H. Platelets activated by collagen through immunoreceptor tyrosine-based activation motif play pivotal role in initiation and generation of neointimal hyperplasia after vascular injury. Circulation. 2002;105:912-916.
97. Hage FG. C-reactive protein and hypertension. J Hum Hypertens. 2014;28:410-415. doi:10.1038/jhh.2013.111.
98. Vongpatanasin W, Thomas GD, Schwartz R, Cassis LA, Osborne-Lawrence S, Hahner L, Gibson LL, Black S, Samols D, Shaul PW. C-reactive protein causes downregulation of vascular angiotensin subtype 2 receptors and systolic hypertension in mice. Circulation. 2007;115:1020-1028. doi:10.1161/CIRCULATIONAHA.106.664854.
99. Guan H, Wang P, Hui R, Edin ML, Zeldin DC, Wang DW. Adenoassociated virus-mediated human C-reactive protein gene delivery causes endothelial dysfunction and hypertension in rats. Clin Chem. 2009;55:274-284. doi:10.1373/clinchem.2008.115857.
100. Pravenec M, Kajiya T, Zídek V, Landa V, Mlejnek P, Simáková M, Silhavý J, Malínská H, Oliyarnyk O, Kazdová L, Fan J, Wang J, Kurtz TW. Effects of human C-reactive protein on pathogenesis of features of the metabolic syndrome. Hypertension. 2011;57:731-737. doi:10.1161/HYPERTENSIONAHA.110.164350.
101. Pietilä KO, Harmoinen AP, Jokiniitty J, Pasternack AI. Serum C-reactive protein concentration in acute myocardial infarction and its relationship to mortality during 24 months of follow-up in patients under thrombolytic treatment. Eur Heart J. 1996;17:1345-1349.
102. Suleiman M, Aronson D, Reisner SA, Kapeliovich MR, Markiewicz W, Levy Y, Hammerman H. Admission C-reactive protein levels and 30-day mortality in patients with acute myocardial infarction. Am J Med. 2003;115:695-701.
103. Suleiman M, Khatib R, Agmon Y, Mahamid R, Boulos M, Kapeliovich M, Levy Y, Beyar R, Markiewicz W, Hammerman H, Aronson D. Early inflammation and risk of long-term development of heart failure and mortality in survivors of acute myocardial infarction predictive role of C-reactive protein. J Am Coll Cardiol. 2006;47:962-968. doi:10.1016/j. jacc.2005.10.055.
104. Griselli M, Herbert J, Hutchinson WL, Taylor KM, Sohail M, Krausz T, Pepys MB. C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med. 1999;190:1733-1740.
105. Pepys MB, Hirschfield GM, Tennent GA, et al. Targeting C-reactive protein for the treatment of cardiovascular disease. Nature. 2006;440:1217-1221. doi:10.1038/nature04672.
106. Szalai AJ, McCrory MA, Xing D, Hage FG, Miller A, Oparil S, Chen YF, Mazzone M, Early R, Henry SP, Zanardi TA, Graham MJ, Crooke RM. Inhibiting C-reactive protein for the treatment of cardiovascular disease: promising evidence from rodent models. Mediators Inflamm. 2014;2014:353614. doi:10.1155/2014/353614.
107. Casas JP, Shah T, Hingorani AD, Danesh J, Pepys MB. C-reactive protein and coronary heart disease: a critical review. J Intern Med. 2008;264:295-314. doi:10.1111/j.1365-2796.2008.02015.x.
108. Festa A, D'Agostino R Jr, Howard G, Mykkänen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000;102:42-47.
109. Haffner SM. Insulin resistance, inflammation, and the prediabetic state. Am J Cardiol. 2003;92:18J-26J.
110. Pradhan AD, Cook NR, Buring JE, Manson JE, Ridker PM. C-reactive protein is independently associated with fasting insulin in nondiabetic women. Arterioscler Thromb Vasc Biol. 2003;23:650-655. doi:10.1161/01.ATV.0000065636.15310.9C.
111. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286:327-334.
112. Tanigaki K, Vongpatanasin W, Barrera JA, Atochin DN, Huang PL, Bonvini E, Shaul PW, Mineo C. C-reactive protein causes insulin resistance in mice through Fc? receptor IIB-mediated inhibition of skeletal muscle glucose delivery. Diabetes. 2013;62:721-731. doi:10.2337/db12-0133.
113. Vlaicu R, Rus HG, Niculescu F, Cristea A. Immunoglobulins and complement components in human aortic atherosclerotic intima. Atherosclerosis. 1985;55:35-50.
114. Döring Y, Manthey HD, Drechsler M, et al. Auto-antigenic protein-DNA complexes stimulate plasmacytoid dendritic cells to promote atherosclerosis. Circulation. 2012;125:1673-1693. doi:10.1161/CIRCULATIONAHA.111.046755.
115. Tsimikas S, Brilakis ES, Lennon RJ, Miller ER, Witztum JL, McConnell JP, Kornman KS, Berger PB. Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events. J Lipid Res. 2007;48:425-433. doi:10.1194/jlr. M600361-JLR200.
116. Zhang X, He M, Cheng L, Chen Y, Zhou L, Zeng H, Pockley AG, Hu FB, Wu T. Elevated heat shock protein 60 levels are associated with higher risk of coronary heart disease in Chinese. Circulation. 2008;118:2687-2693. doi:10.1161/CIRCULATIONAHA.108.781856.
117. Meraviglia MV, Maggi E, Bellomo G, Cursi M, Fanelli G, Minicucci F. Autoantibodies against oxidatively modified lipoproteins and progression of carotid restenosis after carotid endarterectomy. Stroke. 2002;33:1139-1141.
118. Moohebati M, Kabirirad V, Ghayour-Mobarhan M, Esmaily H, Tavallaie S, Akhavan Rezayat A, Pourghadamyari H, Sahebkar A. Investigation of serum oxidized low-density lipoprotein IgG levels in patients with angiographically defined coronary artery disease. Int J Vasc Med. 2014;2014:845960. doi:10.1155/2014/845960.
119. Tsiantoulas D, Diehl CJ, Witztum JL, Binder CJ. B cells and humoral immunity in atherosclerosis. Circ Res. 2014;114:1743-1756. doi:10.1161/CIRCRESAHA.113.301145.
120. Ravandi A, Boekholdt SM, Mallat Z, Talmud PJ, Kastelein JJ, Wareham NJ, Miller ER, Benessiano J, Tedgui A, Witztum JL, Khaw KT, Tsimikas S. Relationship of IgG and IgM autoantibodies and immune complexes to oxidized LDL with markers of oxidation and inflammation and cardiovascular events: results from the EPIC-Norfolk Study. J Lipid Res. 2011;52:1829-1836. doi:10.1194/jlr.M015776.
121. Ebringer A, Doyle AE. Raised serum IgG levels in hypertension. Br Med J. 1970;2:146-148.
122. Gudbrandsson T, Hansson L, Herlitz H, Lindholm L, Nilsson LA. Immunological changes in patients with previous malignant essential hypertension. Lancet. 1981;1:406-408.
123. Hilme E, Herlitz H, Söderström T, Hansson L. Increased secretion of immunoglobulins in malignant hypertension. J Hypertens. 1989;7:91-95.
124. Suryaprabha P, Padma T, Rao UB. Increased serum IgG levels in essential hypertension. Immunol Lett. 1984;8:143-145.
125. Chan CT, Lieu M, Toh BH, Kyaw TS, Bobik A, Sobey CG, Drummond GR. Antibodies in the pathogenesis of hypertension. Biomed Res Int. 2014;2014:504045. doi:10.1155/2014/504045.
126. McMahon M, Hahn BH. Atherosclerosis and systemic lupus erythematosus: mechanistic basis of the association. Curr Opin Immunol. 2007;19:633-639. doi:10.1016/j.coi.2007.11.001.
127. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387-1397. doi:10.1056/NEJMoa032804.
128. Buckley DI, Fu R, Freeman M, Rogers K, Helfand M. C-reactive protein as a risk factor for coronary heart disease: a systematic review and metaanalyses for the U.S. Preventive Services Task Force. Ann Intern Med. 2009;151:483-495.
129. Albert MA, Danielson E, Rifai N, Ridker PM; PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001;286:64-70.
130. Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, Orazem J, Magorien RD, O'Shaughnessy C, Ganz P; Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med. 2005;352:29-38. doi:10.1056/NEJMoa042000.
131. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207. doi:10.1056/NEJMoa0807646.
132. Hage FG, Szalai AJ. The role of C-reactive protein polymorphisms in inflammation and cardiovascular risk. Curr Atheroscler Rep. 2009;11:124-130.
133. Dehghan A, Dupuis J, Barbalic M, et al. Meta-analysis of genomewide association studies in >80 000 subjects identifies multiple loci for C-reactive protein levels. Circulation. 2011;123:731-738. doi:10.1161/CIRCULATIONAHA.110.948570.
134. Nordestgaard BG. Does elevated C-reactive protein cause human atherothrombosis? Novel insights from genetics, intervention trials, and elsewhere. Curr Opin Lipidol. 2009;20:393-401. doi:10.1097/MOL.0b013e3283307bfe.
135. Wensley F, Gao P, Burgess S, Kaptoge S, et al. Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. BMJ 2011;342:d548.
136. Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. C-reactive protein and the risk of developing hypertension. JAMA. 2003;290:2945-2951. doi:10.1001/jama.290.22.2945.
137. Wang TJ, Gona P, Larson MG, Levy D, Benjamin EJ, Tofler GH, Jacques PF, Meigs JB, Rifai N, Selhub J, Robins SJ, Newton-Cheh C, Vasan RS. Multiple biomarkers and the risk of incident hypertension. Hypertension. 2007;49:432-438. doi:10.1161/01.HYP.0000256956.61872.aa.
138. Davey Smith G, Lawlor DA, Harbord R, Timpson N, Rumley A, Lowe GD, Day IN, Ebrahim S. Association of C-reactive protein with blood pressure and hypertension: life course confounding and mendelian randomization tests of causality. Arterioscler Thromb Vasc Biol. 2005;25:1051-1056. doi:10.1161/01.ATV.0000160351.95181.d0.
139. Komurcu-Bayrak E, Erginel-Unaltuna N, Onat A, Ozsait B, Eklund C, Hurme M, Mononen N, Laaksonen R, Hergenc G, Lehtimäki T. Association of C-reactive protein (CRP) gene allelic variants with serum CRP levels and hypertension in Turkish adults. Atherosclerosis. 2009;206:474-479. doi:10.1016/j.atherosclerosis.2009.03.030.
140. Zhao Y, Wang H, Liu S, Zhao X, Chen Y, Yang Y, Wang W, Wu Y, Chen A, Tang J, Yao Y, Li Y, Chen J, Shen C, Yang S. Association study of CRP gene polymorphism and hypertension in Han Chinese population. Gene. 2013;512:41-46. doi:10.1016/j.gene.2012.09.107.
141. Kong H, Qian YS, Tang XF, Zhang J, Gao PJ, Zhang Y, Zhu DL. C-reactive protein (CRP) gene polymorphisms, CRP levels and risk of incident essential hypertension: findings from an observational cohort of Han Chinese. Hypertens Res. 2012;35:1019-1023. doi:10.1038/hr.2012.89.
142. Hong EP, Kim DH, Suh JG, Park JW. Genetic risk assessment for cardiovascular disease with seven genes associated with plasma C-reactive protein concentrations in Asian populations. Hypertens Res. 2014;37:692-698. doi:10.1038/hr.2014.56.
143. Ratcliffe NR, Kennedy SM, Morganelli PM. Immunocytochemical detection of Fcgamma receptors in human atherosclerotic lesions. Immunol Lett. 2001;77:169-174.
144. Gavasso S, Nygård O, Pedersen ER, Aarseth JH, Bleie O, Myhr KM, Vedeler CA. Fcgamma receptor IIIA polymorphism as a risk-factor for coronary artery disease. Atherosclerosis. 2005;180:277-282. doi:10.1016/j.atherosclerosis.2004.12.011.
145. Raaz D, Herrmann M, Ekici AB, Klinghammer L, Lausen B, Voll RE, Leusen JH, van de Winkel JG, Daniel WG, Reis A, Garlichs CD. FcgammaRIIa genotype is associated with acute coronary syndromes as first manifestation of coronary artery disease. Atherosclerosis. 2009;205:512-516. doi:10.1016/j.atherosclerosis.2009.01.013.
146. Raaz-Schrauder D, Ekici AB, Munoz LE, Klinghammer L, Voll RE, Leusen JH, van de Winkel JG, Reis A, Schett G, Garlichs CD, Herrmann M. Patients with unstable angina pectoris show an increased frequency of the Fc gamma RIIa R131 allele. Autoimmunity. 2012;45:556-564. do i:10.3109/08916934.2012.682665.
147. van der Meer IM, Witteman JC, Hofman A, Kluft C, de Maat MP. Genetic variation in Fcgamma receptor IIa protects against advanced peripheral atherosclerosis. The Rotterdam Study. Thromb Haemost. 2004;92:1273-1276. doi:10.1267/THRO04061273.
148. Schneider MP, Leusen JH, Herrmann M, Garlichs CD, Amann K, John S, Schmieder RE. The Fc? receptor IIA R131H gene polymorphism is associated with endothelial function in patients with hypercholesterolaemia. Atherosclerosis. 2011;218:411-415. doi:10.1016/j. atherosclerosis.2011.07.009.
149. Sämpi M, Ukkola O, Païvänsalo M, Kesäniemi YA, Hörkkö S. Early atherosclerosis and IgG2 to bacteria are associated with FcgammaRIIa genotype in non-smokers. Eur J Clin Invest. 2009;39:517-526. doi:10.1111/j.1365-2362.2009.02138.x.
150. Gardemann A, Horstmann A, Santoso S. Fc gamma RIIa-R131H polymorphism: its impact on coronary heart disease in a German cohort. Thromb Haemost. 2003;90:1218-1220. doi:10.1267/THRO03061218.
151. Karakas M, Hoffmann MM, Vollmert C, Rothenbacher D, Meisinger C, Winkelmann B, Khuseyinova N, Böhm BO, Illig T, März W, Koenig W. Genetic variation in Fc gamma receptor IIa and risk of coronary heart disease: negative results from two large independent populations. BMC Med Genet. 2009;10:46. doi:10.1186/1471-2350-10-46.
152. Mollaki V, Steeds RP, Samani NJ, Channer KS, Daly ME. The FcgammaRIIa His131Arg polymorphism and its association with myocardial infarction. J Thromb Haemost. 2004;2:1014-1015. doi:10.1111/j.1538-7836.2004.00750.x.
153. Murphy A, White A, Nair R, Kingwell B, Duffy S, Chin-Dusting J, Woollard K. C-reactive protein and Fc gamma RIIa functional polymorphisms are not associated with clinical presentation of stable and unstable angina. Thromb Haemost. 2007;97:681-682.
154. Zuniga R, Markowitz GS, Arkachaisri T, Imperatore EA, D'Agati VD, Salmon JE. Identification of IgG subclasses and C-reactive protein in lupus nephritis: the relationship between the composition of immune deposits and FCgamma receptor type IIA alleles. Arthritis Rheum. 2003;48:460-470. doi:10.1002/art.10930.
155. Sanders LA, Feldman RG, Voorhorst-Ogink MM, de Haas M, Rijkers GT, Capel PJ, Zegers BJ, van de Winkel JG. Human immunoglobulin G (IgG) Fc receptor IIA (CD32) polymorphism and IgG2-mediated bacterial phagocytosis by neutrophils. Infect Immun. 1995;63:73-81.
156. Pfeiffer JR, Howes PS, Waters MA, Hynes ML, Schnurr PP, Demidenko E, Bech FR, Morganelli PM. Levels of expression of Fcgamma receptor IIA (CD32) are decreased on peripheral blood monocytes in patients with severe atherosclerosis. Atherosclerosis. 2001;155:211-218.
157. Calverley DC, Brass E, Hacker MR, Tsao-Wei DD, Espina BM, Pullarkat VA, Hodis HN, Groshen S. Potential role of platelet FcgammaRIIA in collagen-mediated platelet activation associated with atherothrombosis. Atherosclerosis. 2002;164:261-267.
158. Smith KG, Clatworthy MR. FcgammaRIIB in autoimmunity and infection: evolutionary and therapeutic implications. Nat Rev Immunol. 2010;10:328-343. doi:10.1038/nri2762.
159. Kyogoku C, Dijstelbloem HM, Tsuchiya N, Hatta Y, Kato H, Yamaguchi A, Fukazawa T, Jansen MD, Hashimoto H, van de Winkel JG, Kallenberg CG, Tokunaga K. Fcgamma receptor gene polymorphisms in Japanese patients with systemic lupus erythematosus: contribution of FCGR2B to genetic susceptibility. Arthritis Rheum. 2002;46:1242-1254. doi:10.1002/art.10257.
160. Li X, Wu J, Carter RH, Edberg JC, Su K, Cooper GS, Kimberly RP. A novel polymorphism in the Fcgamma receptor IIB (CD32B) transmembrane region alters receptor signaling. Arthritis Rheum. 2003;48:3242-3252. doi:10.1002/art.11313.
161. Floto RA, Clatworthy MR, Heilbronn KR, Rosner DR, MacAry PA, Rankin A, Lehner PJ, Ouwehand WH, Allen JM, Watkins NA, Smith KG. Loss of function of a lupus-associated FcgammaRIIb polymorphism through exclusion from lipid rafts. Nat Med. 2005;11:1056-1058. doi:10.1038/nm1288.
162. Dries DL, Victor RG, Rame JE, Cooper RS, Wu X, Zhu X, Leonard D, Ho SI, Wu Q, Post W, Drazner MH. Corin gene minor allele defined by 2 missense mutations is common in blacks and associated with high blood pressure and hypertension. Circulation. 2005;112:2403-2410. doi:10.1161/CIRCULATIONAHA.105.568881.
163. Khera A, McGuire DK, Murphy SA, Stanek HG, Das SR, Vongpatanasin W, Wians FH Jr, Grundy SM, de Lemos JA. Race and gender differences in C-reactive protein levels. J Am Coll Cardiol. 2005;46:464-469. doi:10.1016/j.jacc.2005.04.051.
164. Khera A, Vega GL, Das SR, Ayers C, McGuire DK, Grundy SM, de Lemos JA. Sex differences in the relationship between C-reactive protein and body fat. J Clin Endocrinol Metab. 2009;94:3251-3258. doi:10.1210/jc.2008-2406.
165. Khera A, de Lemos JA, Peshock RM, Lo HS, Stanek HG, Murphy SA, Wians FH Jr, Grundy SM, McGuire DK. Relationship between C-reactive protein and subclinical atherosclerosis: the Dallas Heart Study. Circulation. 2006;113:38-43. doi:10.1161/CIRCULATIONAHA.105.575241.
166. Grundy SM, Adams-Huet B, Vega GL. Variable contributions of fat content and distribution to metabolic syndrome risk factors. Metab Syndr Relat Disord. 2008;6:281-288. doi:10.1089/met.2008.0026.
167. Kozlitina J, Boerwinkle E, Cohen JC, Hobbs HH. Dissociation between APOC3 variants, hepatic triglyceride content and insulin resistance. Hepatology. 2011;53:467-474. doi:10.1002/hep.24072.
168. Victor RG, Haley RW, Willett DL, Peshock RM, Vaeth PC, Leonard D, Basit M, Cooper RS, Iannacchione VG, Visscher WA, Staab JM, Hobbs HH; Dallas Heart Study Investigators. The Dallas Heart Study: a population-based probability sample for the multidisciplinary study of ethnic differences in cardiovascular health. Am J Cardiol. 2004;93:1473-1480. doi:10.1016/j.amjcard.2004.02.058.
169. Vaeth PA, Willett DL. Level of acculturation and hypertension among Dallas County Hispanics: findings from the Dallas Heart Study. Ann Epidemiol. 2005;15:373-380. doi:10.1016/j.annepidem.2004.11.003.
170. Flack JM, Sica DA, Bakris G, Brown AL, Ferdinand KC, Grimm RH Jr, Hall WD, Jones WE, Kountz DS, Lea JP, Nasser S, Nesbitt SD, Saunders E, Scisney-Matlock M, Jamerson KA; International Society on Hypertension in Blacks. Management of high blood pressure in Blacks: an update of the International Society on Hypertension in Blacks consensus statement. Hypertension. 2010;56:780-800. doi:10.1161/HYPERTENSIONAHA.110.152892.
171. Redmond N, Baer HJ, Hicks LS. Health behaviors and racial disparity in blood pressure control in the national health and nutrition examination survey. Hypertension. 2011;57:383-389. doi:10.1161/HYPERTENSIONAHA.110.161950.
172. Faruque MU, Chen G, Doumatey A, Huang H, Zhou J, Dunston GM, Rotimi CN, Adeyemo AA. Association of ATP1B1, RGS5 and SELE polymorphisms with hypertension and blood pressure in African-Americans. J Hypertens. 2011;29:1906-1912. doi:10.1097/HJH.0b013e32834b000d.
173. Chang YP, Liu X, Kim JD, Ikeda MA, Layton MR, Weder AB, Cooper RS, Kardia SL, Rao DC, Hunt SC, Luke A, Boerwinkle E, Chakravarti A. Multiple genes for essential-hypertension susceptibility on chromosome 1q. Am J Hum Genet. 2007;80:253-264. doi:10.1086/510918.
174. Tobin MD, Sheehan NA, Scurrah KJ, Burton PR. Adjusting for treatment effects in studies of quantitative traits: antihypertensive therapy and systolic blood pressure. Stat Med. 2005;24:2911-2935. doi:10.1002/sim.2165.